Compare NUVB & ACDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUVB | ACDC |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | 298 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | N/A | 2021 |
| Metric | NUVB | ACDC |
|---|---|---|
| Price | $4.75 | $6.08 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 8 | 2 |
| Target Price | ★ $11.38 | $5.50 |
| AVG Volume (30 Days) | ★ 4.2M | 1.3M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,941,800,000.00 |
| Revenue This Year | $203.82 | N/A |
| Revenue Next Year | $58.18 | $11.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.57 | $3.08 |
| 52 Week High | $9.75 | $10.70 |
| Indicator | NUVB | ACDC |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 37.45 |
| Support Level | $4.07 | $6.05 |
| Resistance Level | $5.23 | $7.66 |
| Average True Range (ATR) | 0.25 | 0.45 |
| MACD | 0.02 | -0.18 |
| Stochastic Oscillator | 71.35 | 8.01 |
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
ProFrac Holding Corp is a technology-focused, vertically integrated energy services company providing hydraulic fracturing, proppant production, completion services, and related products, including distributed power generation, to upstream oil and natural gas companies in the United States. The Company operates through four segments: Stimulation Services, Proppant Production, Manufacturing, and Flotek. The Stimulation Services segment, which generates maximum revenue, provides hydraulic fracturing services using mobile units and auxiliary equipment. The Proppant Production segment supplies proppant, the Manufacturing segment sells engineered products such as pumps, valves, and piping, and Flotek is a chemistry and data technology company serving the E&P industry.